Nitroglycerin (Glyceryl Trinitrate)
Intravenous vasodilator for acute cardiovascular emergencies
Quick Facts About Nitroglycerin
Key Takeaways About Nitroglycerin
- Rapid-acting vasodilator: Intravenous nitroglycerin begins working within 1–2 minutes, making it essential for acute cardiovascular emergencies
- Never combine with PDE-5 inhibitors: Combining nitroglycerin with sildenafil (Viagra), tadalafil (Cialis), or vardenafil (Levitra) can cause life-threatening hypotension
- Tolerance develops with continuous use: Effectiveness diminishes within 24–48 hours of continuous infusion; nitrate-free intervals help prevent this
- Hospital-only administration: The intravenous formulation requires continuous blood pressure monitoring and controlled infusion equipment
- Headache is the most common side effect: Occurring in more than 1 in 10 patients, it typically improves with dose adjustment or continued use
What Is Nitroglycerin and What Is It Used For?
Nitroglycerin is an organic nitrate vasodilator that relaxes blood vessel walls by releasing nitric oxide. The intravenous form (Nitroglycerin Macure, 1 mg/mL) is used in hospitals to treat acute angina pectoris, decompensated heart failure with pulmonary edema, hypertensive emergencies, and to control blood pressure during cardiac surgery.
Nitroglycerin, also known as glyceryl trinitrate (GTN), is one of the oldest and most widely used cardiovascular medications in the world. Its medical applications were first discovered in the 1870s, when workers in dynamite factories noticed that handling the compound relieved their chest pain. Today, it remains a cornerstone of acute cardiac care, recommended by every major international cardiology guideline, including the European Society of Cardiology (ESC), the American College of Cardiology (ACC), and the American Heart Association (AHA).
The drug works by being converted into nitric oxide (NO) inside the smooth muscle cells that line blood vessels. Nitric oxide activates an enzyme called guanylate cyclase, which increases levels of cyclic guanosine monophosphate (cGMP). This biochemical cascade causes the smooth muscle to relax, widening the blood vessels. At lower therapeutic doses, nitroglycerin predominantly dilates veins (venodilation), reducing the volume of blood returning to the heart (preload). At higher doses, it also dilates arteries (arteriodilation), reducing the resistance the heart must pump against (afterload).
This dual mechanism is what makes nitroglycerin so effective in acute cardiac settings. By reducing both preload and afterload, it decreases the heart's oxygen demand while simultaneously improving blood flow through the coronary arteries that supply the heart muscle itself. This is particularly beneficial in patients experiencing myocardial ischemia (inadequate blood flow to the heart muscle), where the balance between oxygen supply and demand is critically disrupted.
Primary Clinical Indications
Intravenous nitroglycerin is indicated for several acute cardiovascular conditions where rapid, precisely controlled vasodilation is required:
- Acute angina pectoris – Chest pain caused by insufficient blood flow to the heart, particularly unstable angina and acute coronary syndromes where immediate symptom relief is critical
- Acute decompensated heart failure – Especially when accompanied by pulmonary edema (fluid in the lungs), where reducing preload rapidly improves breathing and cardiac function
- Hypertensive emergencies – Dangerously elevated blood pressure requiring immediate, controlled reduction to prevent organ damage
- Perioperative blood pressure control – During and after cardiac surgery, coronary artery bypass grafting, or other procedures where precise hemodynamic control is essential
- Controlled hypotension during surgery – To reduce bleeding in surgical fields by carefully lowering blood pressure
Nitroglycerin is available in many different formulations beyond the intravenous form described here, including sublingual tablets, oral sprays, transdermal patches, and ointments. Each formulation has different onset times, durations of action, and clinical uses. This article focuses specifically on the intravenous infusion solution (1 mg/mL), which is used exclusively in hospital settings under medical supervision.
How Nitroglycerin Differs from Other Nitrates
Nitroglycerin belongs to a family of drugs called organic nitrates, which also includes isosorbide dinitrate and isosorbide mononitrate. While all organic nitrates share the same basic mechanism of action (nitric oxide release), nitroglycerin is unique in several important respects. It has the fastest onset of action of any nitrate (1–2 minutes intravenously), the shortest duration of effect (3–5 minutes after stopping the infusion), and the greatest venodilatory potency at low doses. These pharmacokinetic properties make intravenous nitroglycerin the preferred choice when rapid, fine-tuned hemodynamic control is needed in critical care settings.
What Should You Know Before Taking Nitroglycerin?
Nitroglycerin must not be used if you have taken phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil), have severe hypotension, severe aortic or mitral stenosis, constrictive pericarditis, cardiac tamponade, or conditions associated with elevated intracranial pressure. Always inform your healthcare team of all medications you are taking.
Because intravenous nitroglycerin is administered in a hospital setting by trained medical professionals, the prescribing physician will evaluate your complete medical history and current medications before initiating treatment. However, understanding the key contraindications and precautions is important for patients and caregivers.
Contraindications
Nitroglycerin must not be used in the following situations, as the risks significantly outweigh any potential benefits:
- Concurrent use of PDE-5 inhibitors – Sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), or riociguat (Adempas). This combination can cause severe, potentially fatal hypotension. At least 24 hours must elapse after sildenafil or vardenafil use, and at least 48 hours after tadalafil use, before nitroglycerin can be safely administered.
- Severe hypotension – Systolic blood pressure below 90 mmHg, as nitroglycerin will further lower blood pressure and may cause cardiovascular collapse.
- Hypovolemia – Patients with severe volume depletion (e.g., from dehydration, hemorrhage, or diuretic overuse) are at very high risk of precipitous blood pressure drops.
- Severe aortic stenosis – In patients with significant narrowing of the aortic valve, vasodilation can lead to dangerous hypotension because cardiac output cannot increase to compensate.
- Constrictive pericarditis or cardiac tamponade – These conditions restrict the heart's ability to fill with blood, and reducing preload with nitroglycerin can critically reduce cardiac output.
- Hypertrophic obstructive cardiomyopathy (HOCM) – Vasodilation can worsen the obstruction of blood flow out of the heart.
- Elevated intracranial pressure – Nitroglycerin can increase intracranial pressure, making it dangerous in patients with head trauma or cerebral hemorrhage.
- Known hypersensitivity – Allergy to nitroglycerin or any other organic nitrate.
The interaction between nitroglycerin and phosphodiesterase-5 (PDE-5) inhibitors such as sildenafil (Viagra) is one of the most dangerous drug interactions in cardiovascular medicine. Both drugs lower blood pressure through complementary mechanisms, and their combined effect can produce catastrophic, treatment-resistant hypotension that may be fatal. Emergency physicians must always ask about recent PDE-5 inhibitor use before administering any nitrate.
Warnings and Precautions
Nitroglycerin should be used with particular caution in the following situations, where the benefit-risk balance must be carefully considered by the treating physician:
- Acute myocardial infarction – While nitroglycerin can be beneficial for symptom relief, it should be used cautiously in right ventricular infarction, where reducing preload can critically reduce cardiac output.
- Hypothyroidism – Patients with an underactive thyroid may be more sensitive to the hypotensive effects of nitroglycerin.
- Hepatic impairment – Severe liver disease may alter the metabolism of nitroglycerin, potentially prolonging its effects.
- Renal impairment – While dose adjustment is not typically required, patients with kidney disease should be monitored closely.
- Anemia – Severely anemic patients may be more susceptible to the hypotensive effects because their oxygen-carrying capacity is already compromised.
- Glaucoma – Nitroglycerin may increase intraocular pressure in some patients.
Pregnancy and Breastfeeding
Nitroglycerin should only be used during pregnancy if the potential benefit to the mother clearly justifies the potential risk to the fetus. There is limited data on the use of intravenous nitroglycerin in pregnant women, though it has been used off-label in some obstetric emergencies, including severe pre-eclampsia and acute uterine relaxation (tocolysis). Animal studies have not demonstrated significant teratogenic effects, but human data are insufficient to rule out all risks.
It is not known whether nitroglycerin passes into breast milk. Given that intravenous nitroglycerin is used in acute hospital settings with a very short duration of action, the risk to breastfed infants is generally considered minimal. However, the decision to continue breastfeeding during and after treatment should be made in consultation with the treating physician, weighing the clinical necessity of the treatment against any potential risk to the infant.
How Does Nitroglycerin Interact with Other Drugs?
Nitroglycerin has clinically significant interactions with PDE-5 inhibitors (absolutely contraindicated), other blood pressure-lowering medications (additive hypotension), heparin (reduced anticoagulant effect), and ergot alkaloids. All antihypertensives, diuretics, and vasodilators can amplify nitroglycerin's blood pressure-lowering effect.
Drug interactions with nitroglycerin are primarily pharmacodynamic in nature, meaning they involve the combined effects of drugs on blood pressure and cardiovascular function rather than changes in drug metabolism. Because intravenous nitroglycerin is administered in a closely monitored hospital environment, healthcare professionals can observe and manage most interactions in real time. Nevertheless, understanding these interactions is crucial for safe and effective therapy.
Major Interactions
| Drug/Class | Interaction | Severity | Management |
|---|---|---|---|
| Sildenafil (Viagra) | Severe, potentially fatal hypotension through synergistic vasodilation | Contraindicated | Wait at least 24 hours after sildenafil before nitroglycerin |
| Tadalafil (Cialis) | Severe, potentially fatal hypotension; longer duration than sildenafil | Contraindicated | Wait at least 48 hours after tadalafil before nitroglycerin |
| Vardenafil (Levitra) | Severe, potentially fatal hypotension through synergistic vasodilation | Contraindicated | Wait at least 24 hours after vardenafil before nitroglycerin |
| Riociguat (Adempas) | Synergistic hypotension via cGMP pathway amplification | Contraindicated | Must not be combined; alternative therapy required |
| Heparin | Nitroglycerin may reduce heparin's anticoagulant effect | Major | Monitor aPTT closely; increase heparin dose as needed |
| Alteplase (tPA) | Reduced thrombolytic efficacy; nitroglycerin may impair coronary flow | Major | Use lowest effective nitroglycerin dose during thrombolysis |
Moderate Interactions
The following drug classes can enhance the blood pressure-lowering effects of nitroglycerin, potentially requiring dose adjustments or closer monitoring:
- Beta-blockers (e.g., metoprolol, bisoprolol, atenolol) – Additive blood pressure and heart rate reduction. Often used intentionally in combination, but requires careful dose titration.
- Calcium channel blockers (e.g., amlodipine, verapamil) – Additive vasodilation and hypotension risk. Verapamil may also decrease nitroglycerin clearance.
- ACE inhibitors (e.g., enalapril, ramipril) and ARBs (e.g., losartan, candesartan) – Enhanced hypotensive effect.
- Diuretics (e.g., furosemide, hydrochlorothiazide) – Volume depletion increases the risk of significant hypotension.
- Tricyclic antidepressants (e.g., amitriptyline) – May enhance the orthostatic hypotensive effects of nitroglycerin.
- Alcohol – Ethanol potentiates the vasodilatory effects of nitroglycerin and can cause severe hypotension.
- Ergot alkaloids (e.g., dihydroergotamine) – Nitroglycerin may increase the bioavailability of dihydroergotamine; concurrent use is generally avoided.
What Is the Correct Dosage of Nitroglycerin?
Intravenous nitroglycerin dosing is highly individualized and titrated to clinical response. The typical starting dose for adults is 5–10 micrograms per minute, gradually increased in increments of 5–10 mcg/min every 3–5 minutes until the desired hemodynamic effect is achieved. Maximum doses of 200–400 mcg/min may be needed in some clinical situations. Dosing must always be guided by continuous blood pressure monitoring.
Intravenous nitroglycerin dosing is fundamentally different from most medications because there is no fixed dose. Instead, the infusion rate is titrated (gradually adjusted) based on the patient's clinical response, primarily blood pressure and symptom relief. This requires continuous hemodynamic monitoring, typically with an arterial line or frequent non-invasive blood pressure measurements, in an intensive care unit or monitored care setting.
Adults
Acute Angina / Acute Coronary Syndrome
Starting dose: 5–10 mcg/min intravenous infusion
Titration: Increase by 5–10 mcg/min every 3–5 minutes
Target: Symptom relief or 10% reduction in mean arterial pressure (MAP) in normotensive patients; up to 30% reduction in hypertensive patients
Maximum: Typically 200 mcg/min, though higher doses may be used under close supervision
Acute Decompensated Heart Failure
Starting dose: 10–20 mcg/min intravenous infusion
Titration: Increase by 5–20 mcg/min every 3–5 minutes
Target: Improvement in symptoms of congestion (dyspnea, pulmonary edema) while maintaining systolic blood pressure above 90 mmHg
Maximum: Up to 400 mcg/min in severe cases
Hypertensive Emergency
Starting dose: 5 mcg/min intravenous infusion
Titration: Increase by 5 mcg/min every 3–5 minutes
Target: Gradual blood pressure reduction of 25% within the first hour, then to 160/100 mmHg over the next 2–6 hours (per ESC/AHA guidelines)
Maximum: Up to 200 mcg/min
Perioperative Blood Pressure Control
Starting dose: 5 mcg/min intravenous infusion, started before or during surgery
Titration: Increase in 5–10 mcg/min increments
Target: Blood pressure targets as determined by the surgical and anaesthesia team
Maximum: Up to 200 mcg/min
Children
The use of intravenous nitroglycerin in pediatric patients is not well-established and is generally limited to specialized pediatric cardiac intensive care units. When used, doses are typically 0.25–5 mcg/kg/min, titrated to clinical effect. There is limited evidence from controlled trials to guide pediatric dosing, and its use in children should be considered on a case-by-case basis under specialist supervision.
Elderly
Elderly patients may be more sensitive to the hypotensive effects of nitroglycerin due to age-related changes in baroreceptor function, reduced intravascular volume, and often concurrent use of multiple blood pressure-lowering medications. Treatment should be initiated at the lowest effective dose and titrated more slowly than in younger adults. Close hemodynamic monitoring is especially important, as orthostatic hypotension and reflex tachycardia may be more pronounced and clinically significant in older patients.
Missed Dose
The concept of a missed dose does not apply to intravenous nitroglycerin in the same way as oral medications. Since it is administered as a continuous infusion under medical supervision, any interruption in therapy is managed by the healthcare team. If the infusion is accidentally stopped or interrupted, it can be restarted at the previous rate or adjusted according to the patient's current hemodynamic status. There is no need to administer an extra dose to compensate for a brief interruption.
Overdose
Overdose with intravenous nitroglycerin manifests primarily as severe hypotension, which may be accompanied by reflex tachycardia, headache, flushing, dizziness, nausea, vomiting, and syncope (fainting). In severe cases, methemoglobinemia (a condition where hemoglobin cannot effectively carry oxygen) may develop.
Treatment of nitroglycerin overdose is primarily supportive:
- Stop the infusion immediately – Effects typically resolve within 3–5 minutes due to the short half-life
- Trendelenburg position – Elevate the patient's legs to promote venous return
- Intravenous fluids – Rapid volume expansion with normal saline to increase preload
- Vasopressors – Phenylephrine or norepinephrine if hypotension is refractory to fluids
- Methylene blue – 1–2 mg/kg IV for significant methemoglobinemia (methemoglobin level >20%)
Due to the very short half-life of intravenous nitroglycerin, dialysis and hemoperfusion are not useful in overdose management.
What Are the Side Effects of Nitroglycerin?
The most common side effects of intravenous nitroglycerin are headache (very common, affecting more than 1 in 10 patients), hypotension (low blood pressure), dizziness, and reflex tachycardia (increased heart rate). Most side effects are dose-dependent and resolve with dose reduction or discontinuation of the infusion.
Side effects of nitroglycerin are largely predictable extensions of its pharmacological action on blood vessels. As a vasodilator, it lowers blood pressure, which triggers compensatory reflexes (increased heart rate) and can cause symptoms related to reduced blood flow to the brain (dizziness, headache). The severity of most side effects is dose-dependent, meaning they are more likely at higher infusion rates and can usually be managed by reducing the dose.
Very Common (affects more than 1 in 10 patients)
- Headache – The most frequently reported side effect; caused by dilation of cerebral blood vessels. Often severe initially but tends to diminish with continued use (nitrate headache tolerance). Can be managed with paracetamol.
- Hypotension – Dose-dependent decrease in blood pressure; the primary mechanism of therapeutic action but can become excessive. Managed by reducing the infusion rate.
Common (affects 1 in 10 to 1 in 100 patients)
- Dizziness and lightheadedness – Related to hypotension; patients should not attempt to stand or walk without assistance
- Reflex tachycardia – Compensatory increase in heart rate in response to blood pressure lowering
- Nausea and vomiting – May be related to hypotension or direct effects on the gastrointestinal tract
- Flushing – Warmth and redness of the skin, particularly the face and neck, caused by peripheral vasodilation
- Apprehension and restlessness – May occur during acute treatment, partly related to the clinical situation
Uncommon (affects 1 in 100 to 1 in 1,000 patients)
- Syncope (fainting) – Caused by excessive blood pressure reduction
- Paradoxical bradycardia – Slowed heart rate, sometimes seen with very rapid blood pressure drops
- Abdominal pain – Occasionally reported during infusion
- Palpitations – Awareness of increased or irregular heart beat
Rare (affects fewer than 1 in 1,000 patients)
- Methemoglobinemia – A serious condition where hemoglobin is oxidized and cannot carry oxygen effectively. More likely at very high doses or in patients with certain enzyme deficiencies. Treated with methylene blue.
- Allergic reactions – Skin rash, contact dermatitis (more common with transdermal preparations), very rarely anaphylaxis
- Worsening angina – Paradoxical increase in chest pain, potentially due to coronary steal phenomenon or excessive hypotension reducing coronary perfusion pressure
- Increased intracranial pressure – Rarely clinically significant at standard therapeutic doses
A clinically important phenomenon is nitrate tolerance, where the vasodilatory effects of nitroglycerin diminish with continuous or prolonged administration. This can begin as early as 24–48 hours into a continuous infusion. The mechanism involves depletion of sulfhydryl groups and enzyme systems needed to convert nitroglycerin to nitric oxide. Cross-tolerance to other nitrates also develops. Tolerance is managed by incorporating nitrate-free intervals (typically 8–12 hours daily) into long-term therapy, though this is more relevant for transdermal patches and oral long-acting nitrates than for short-term intravenous use in acute settings.
How Should You Store Nitroglycerin?
Nitroglycerin infusion solution should be stored below 25°C, protected from light, and must not be frozen. The solution should be diluted before use and administered through non-PVC infusion sets, as nitroglycerin is significantly adsorbed by PVC (polyvinyl chloride) tubing, which can reduce the delivered dose by up to 80%.
Proper storage and handling of nitroglycerin infusion solution is critical because the drug has specific chemical properties that affect its stability and the amount of drug that reaches the patient.
Storage Conditions
- Temperature: Store below 25°C (77°F). Do not freeze.
- Light protection: Keep the ampoules in the outer carton to protect from light, as nitroglycerin can degrade when exposed to light.
- Shelf life: Refer to the expiry date on the packaging. Once diluted, the solution should be used within 24 hours.
- Do not use if the solution is discolored, cloudy, or contains visible particles.
Administration Equipment
One of the most important practical considerations with intravenous nitroglycerin is the choice of infusion equipment. Nitroglycerin is a lipophilic (fat-soluble) molecule that is significantly adsorbed by PVC (polyvinyl chloride) plastics commonly used in standard intravenous tubing and bags. This adsorption can reduce the amount of drug that actually reaches the patient by 40–80%, depending on the tubing length and flow rate.
To minimize drug loss, nitroglycerin should be administered using:
- Glass bottles for dilution rather than PVC bags
- Polyethylene (PE), polypropylene, or Teflon infusion tubing
- Non-PVC-containing infusion sets specifically designed for nitroglycerin administration
If PVC equipment must be used, healthcare providers need to be aware that higher infusion rates will be required to achieve the desired therapeutic effect, and dose titration will need to account for variable drug loss.
What Does Nitroglycerin Contain?
Nitroglycerin Macure infusion solution contains nitroglycerin as the active ingredient at a concentration of 1 mg/mL. Excipients include glucose, water for injection, and hydrochloric acid and/or sodium hydroxide for pH adjustment. The solution must be diluted before intravenous administration.
Understanding the full composition of the infusion solution is important for patients with known allergies or sensitivities to specific excipients, and for healthcare providers managing patients with conditions such as diabetes (where glucose content may be relevant).
Active Ingredient
- Nitroglycerin (glyceryl trinitrate) – 1 mg per mL of concentrate for solution for infusion
Excipients (Inactive Ingredients)
- Glucose – Used as a stabilizer and solvent component
- Water for injections – Pharmaceutical-grade water serving as the primary solvent
- Hydrochloric acid and/or sodium hydroxide – Used for pH adjustment to ensure the solution is within the appropriate pH range for intravenous administration
The solution is clear and colorless to slightly yellow. It is a concentrate that must be diluted before administration, typically with 5% glucose solution or 0.9% sodium chloride solution (normal saline). The choice of diluent should take into account compatibility with the administration equipment being used.
The glucose content of nitroglycerin infusion solution and its diluent (if 5% glucose is used) should be taken into account when managing blood glucose levels in diabetic patients. The amounts of glucose involved are generally small relative to the total caloric intake, but may be clinically relevant in patients receiving prolonged infusions or those requiring very strict glycemic control.
Frequently Asked Questions About Nitroglycerin
Intravenous nitroglycerin is used to treat acute angina pectoris (chest pain from reduced blood flow to the heart), acute decompensated heart failure with pulmonary edema, hypertensive emergencies, and to control blood pressure during and after cardiac surgery. It works by relaxing blood vessels, reducing the heart's workload, and improving coronary blood flow. The intravenous formulation is administered exclusively in hospital settings under continuous hemodynamic monitoring.
The most common side effects of intravenous nitroglycerin include headache (affects more than 1 in 10 patients), hypotension (low blood pressure), dizziness, lightheadedness, and reflex tachycardia (increased heart rate). Headache is the most frequently reported side effect and typically improves with continued use or dose reduction. Most side effects are dose-dependent and can be managed by adjusting the infusion rate.
No, nitroglycerin must never be used with phosphodiesterase-5 (PDE-5) inhibitors such as sildenafil (Viagra), tadalafil (Cialis), or vardenafil (Levitra). This combination can cause a dangerous, potentially fatal drop in blood pressure. You must wait at least 24 hours after taking sildenafil or vardenafil, and at least 48 hours after taking tadalafil, before nitroglycerin can be administered. This is one of the most clinically significant drug interactions in cardiovascular medicine.
Nitroglycerin tolerance is a well-documented phenomenon where the vasodilatory effects diminish with continuous use, sometimes within 24 to 48 hours. It occurs because the enzyme systems that convert nitroglycerin to nitric oxide become depleted. Tolerance is prevented by incorporating nitrate-free intervals (typically 8 to 12 hours per day). For intravenous use, the infusion rate may need to be periodically increased to maintain efficacy during prolonged administration.
Intravenous nitroglycerin has an extremely rapid onset of action, typically within 1 to 2 minutes of starting the infusion. This makes it ideal for acute cardiovascular emergencies where rapid blood pressure reduction or symptom relief is needed. The effects are also quickly reversible: when the infusion is stopped, hemodynamic effects wear off within 3 to 5 minutes. This rapid onset and offset allows precise, minute-to-minute control of blood pressure and cardiac workload.
Yes, pharmaceutical nitroglycerin is chemically the same compound as the explosive, but it is used in extremely small, dilute concentrations for medical purposes. The medical use dates back to the 1870s, when dynamite factory workers noticed relief from chest pain. In its pharmaceutical form (typically 1 mg/mL solution), nitroglycerin poses no explosive risk whatsoever. It is one of the oldest cardiovascular medications still in active clinical use, with over 150 years of therapeutic history.
References
This article is based on the following peer-reviewed sources, international guidelines, and regulatory documents:
- European Medicines Agency (EMA). Summary of Product Characteristics: Glyceryl Trinitrate Infusion Solution. EMA product database. Available at: www.ema.europa.eu
- Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the Management of Acute Coronary Syndromes. European Heart Journal. 2023;44(38):3720-3826. doi:10.1093/eurheartj/ehad191
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023. Available at: www.who.int
- Joint Formulary Committee. British National Formulary (BNF). London: BMJ Group and Pharmaceutical Press. Glyceryl trinitrate monograph. Available at: bnf.nice.org.uk
- U.S. Food and Drug Administration (FDA). Nitroglycerin Injection Prescribing Information. FDA drug label database. Available at: www.fda.gov
- Divakaran S, Bhatt DL. Nitrates in Cardiovascular Therapeutics. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 12th ed. Elsevier; 2022.
- Munzel T, Daiber A, Gori T. Nitrate Therapy: New Aspects Concerning Molecular Action and Tolerance. Circulation. 2011;123(19):2132-2144. doi:10.1161/CIRCULATIONAHA.110.981407
- Cohn JN, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. New England Journal of Medicine. 1986;314(24):1547-1552. (V-HeFT trial)
- GISSI-3 Investigators. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together in acute myocardial infarction. Lancet. 1994;343(8906):1115-1122.
About the Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in clinical pharmacology, cardiology, and intensive care medicine.
Content developed by physicians specializing in clinical pharmacology and cardiovascular medicine, with expertise in nitrate pharmacotherapy and acute cardiac care protocols.
Independently verified by the iMedic Medical Review Board against current international guidelines (ESC, ACC/AHA, EMA, BNF, WHO) using the GRADE evidence framework.
Evidence standards: All clinical claims in this article are supported by Level 1A evidence (systematic reviews and meta-analyses of randomized controlled trials) or official regulatory documents. The article follows the iMedic Editorial Standards for medical accuracy, independence, and transparency.
Conflict of interest: None. iMedic receives no commercial funding and has no pharmaceutical industry affiliations.